Approaching Unmet Clinical Needs in Polycythemia VeraVideo Categories: Polycythemia Vera
Supported through funding from Incyte
Ken Schaecher, MD, presents his own personal opinion on the challenges of concerns related to costs of treatment by oncologists and why they should not ignore them. Supported through funding from Incyte
Dixie-Lee Esseltine, MD and George Mulligan, PhD explain ixazomib’s mechanism of action and how the drug may fit into the treatment regimen for patients upon approval and beyond.